fon-2021-1367 – First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population
收藏数据链接：
官方服务：
资源简介：
<strong>Table S1 Hazard Ratios with and without Inverse Probability Weights</strong> <strong>Table S2 Multivariate Analysis: Prognostic Factors for Overall Survival</strong>
提供机构：
Taylor & Francis创建时间：
2022-05-17
